MPM Bioimpact LLC increased its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 10.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,428,366 shares of the company's stock after buying an additional 333,470 shares during the period. Trevi Therapeutics accounts for approximately 3.7% of MPM Bioimpact LLC's investment portfolio, making the stock its 8th biggest holding. MPM Bioimpact LLC owned about 3.43% of Trevi Therapeutics worth $21,564,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Wells Fargo & Company MN lifted its position in Trevi Therapeutics by 40.7% in the 4th quarter. Wells Fargo & Company MN now owns 33,050 shares of the company's stock valued at $136,000 after acquiring an additional 9,562 shares in the last quarter. Invesco Ltd. lifted its position in Trevi Therapeutics by 21.2% in the 4th quarter. Invesco Ltd. now owns 23,621 shares of the company's stock valued at $97,000 after acquiring an additional 4,133 shares in the last quarter. Renaissance Technologies LLC lifted its position in Trevi Therapeutics by 42.0% in the 4th quarter. Renaissance Technologies LLC now owns 100,400 shares of the company's stock valued at $414,000 after acquiring an additional 29,700 shares in the last quarter. Raymond James Financial Inc. bought a new position in Trevi Therapeutics in the 4th quarter valued at about $49,000. Finally, Barclays PLC lifted its position in Trevi Therapeutics by 64.1% in the 4th quarter. Barclays PLC now owns 156,267 shares of the company's stock valued at $643,000 after acquiring an additional 61,035 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.
Trevi Therapeutics Stock Up 0.7%
Trevi Therapeutics stock opened at $7.26 on Tuesday. Trevi Therapeutics, Inc. has a 52 week low of $2.36 and a 52 week high of $8.78. The company's 50 day moving average price is $6.95 and its two-hundred day moving average price is $6.32. The stock has a market cap of $884.12 million, a P/E ratio of -17.29 and a beta of 0.71.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. On average, equities analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.
Wall Street Analyst Weigh In
TRVI has been the topic of several recent research reports. Wall Street Zen cut shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. D. Boral Capital reaffirmed a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Needham & Company LLC dropped their price target on shares of Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Raymond James Financial dropped their target price on shares of Trevi Therapeutics from $29.00 to $27.00 and set a "strong-buy" rating on the stock in a research report on Friday, August 8th. Finally, Oppenheimer reissued an "outperform" rating on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to data from MarketBeat.com, Trevi Therapeutics presently has an average rating of "Buy" and an average price target of $20.11.
Check Out Our Latest Stock Analysis on TRVI
Trevi Therapeutics Company Profile
(
Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
See Also
Want to see what other hedge funds are holding TRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
